| Title | Activity of Lactobacillus crispatus isolated from vaginal microbiota against Mycobacterium tuberculosis |
|---|---|
| Author | Youngkyoung Lee1†, Hoonhee Seo2†, Sukyung Kim2, MD Abdur Rahim1, Youjin Yoon1, Jehee Jung1, Saebim Lee2, Chang Beom Ryu3, and Ho-Yeon Song1,2* |
| Address | 1Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan 31151, Republic of Korea, 2Probiotics Microbiome Convergence Center, Soonchunhyang University, Asan 31538, Republic of Korea, 3Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea |
| Bibliography | Journal of Microbiology, 59(11),1019-1030, 2021, |
| DOI | 10.1007/s12275-021-1332-0 |
| Key Words | Mycobacterium tuberculosis, Lactobacillus crispatus PMC 201, probiotics, anti-tuberculosis effect, microbiome |
| Abstract | Tuberculosis, an infectious disease, is caused by Mycobacterium tuberculosis. It remains a significant public health issue around the globe, causing about 1.8 million deaths every year. Drug-resistant M. tuberculosis, including multi-drug-resistant (MDR), extremely-drug-resistant (XDR), and totally drugresistant (TDR) M. tuberculosis, continues to be a threat to public health. In the case of antibiotic-resistant tuberculosis, the treatment effect of conventional antibiotics is low. Side effects caused by high doses over a long period are causing severe problems. To overcome these problems, there is an urgent need to develop a new anti-tuberculosis drug that is different from the existing compound-based antibiotics. Probiotics are defined as live microorganisms conferring health benefits. They can be potential therapeutic agents in this context as the effectiveness of probiotics against different infectious diseases has been well established. Here, we report that Lactobacillus crispatus PMC201 shows a promising effect on tuberculosis isolated from vaginal fluids of healthy Korean women. Lactobacillus crispatus PMC201 reduced M. tuberculosis H37Rv under co-culture conditions in broth and reduced M. tuberculosis H37Rv and XDR M. tuberculosis in macrophages. Lactobacillus crispatus PMC201 was not toxic to a guinea pig model and did not induce dysbiosis in a human intestinal microbial ecosystem simulator. Taken together, these results indicate that L. crispatus PMC201 can be a promising alternative drug candidate in the current tuberculosis drug regime. Further study is warranted to assess the in vivo efficacy and confirm the mode of action of L. crispatus PMC201. |